Advertisement

Construction and Production of an IgG-Like Tetravalent Bispecific Antibody for Enhanced Therapeutic Efficacy

  • Dan Lu
  • Zhenping Zhu
Protocol
Part of the Methods in Molecular Biology™ book series (MIMB, volume 525)

Abstract

In past years, both laboratory and early clinical studies have demonstrated that bispecific antibodies (BsAbs) may have significant potential application in cancer therapy either by targeting tumor cells with cytotoxic agents including effector cells, radionuclides, drugs, and toxins, or by simultaneously blocking two relevant tumor targets, that is, growth factor receptors, thus neutralizing multiple receptor activation and downstream signal transduction pathways. A major obstacle in the development of BsAb has been the difficulty of producing the materials in sufficient quality and quantity by traditional technologies such as the hybrid hybridoma and chemical conjugation methods. The development of IgG-like BsAbs as therapeutic agents will depend heavily on the advances made in the design of recombinant BsAb constructs (or formats) and production efficiency. Here we describe a recombinant method for the construction and production of a novel IgG-like BsAb molecule, using the variable domains of two fully human antibodies as the building blocks.

Key words

Antibody engineering bispecific antibody single-chain fragment recombinant antibody antibody production cancer therapy 

References

  1. 1.
    Kontermann, R. E. (2005) Recombinant bispecific antibodies for cancer therapy. Acta. Pharmacol. Sin. 26, 1–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Kipriyanov, S. M. and Le Gall F. (2004) Recent advances in the generation of bispecific antibodies for tumor immunotherapy. Curr. Opin. Drug Discov. Devel. 7, 233–242.PubMedGoogle Scholar
  3. 3.
    Lum, L. G., and Davol, P. A. (2005) Retargeting T cells and immune effector cells with bispecific antibodies. Cancer Chemother. Biol. Response Modif. 22, 273–291.PubMedGoogle Scholar
  4. 4.
    Marvin, J. S., and Zhu, Z. (2006) Bispecific antibodies for dual-modality cancer therapy: killing two signaling cascades with one stone. Curr. Opin. Drug Discov. Devel. 9, 184–193.PubMedGoogle Scholar
  5. 5.
    Lu, D., Zhang, H., Koo, H., Tonra, J., Balderes, P., Prewett, M., Corcoran, E., Mangalampalli. V/, Bassi. R., Anselma, D., Patel, D., Kang, X., Ludwig, D. L., Hicklin, D. J., Bohlen, P., Witte, L., and Zhu, Z. (2005) A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J. Biol. Chem. 280, 19665–19672.PubMedCrossRefGoogle Scholar
  6. 6.
    Marvin, J. S., and Zhu, Z. (2005) Recombinant approaches to IgG-like bispecific antibodies. Acta. Pharmacol. Sin. 26, 649–658.PubMedCrossRefGoogle Scholar
  7. 7.
    Carter, P. (2001) Bispecific human IgG by design. J. Immunol. Methods 248, 7–15.PubMedCrossRefGoogle Scholar
  8. 8.
    Zuo, Z., Jimenez, X., Witte, L., and Zhu, Z. (2000) An efficient route to the production of an IgG-like bispecific antibody. Protein Eng. 13, 361–367.PubMedCrossRefGoogle Scholar
  9. 9.
    Lu, D., Zhang, H., Ludwig, D., Persaud, A., Jimenez, X., Burtrum, D., Balderes, P., Liu, M., Bohlen, P., Witte, L., and Zhu, Z. (2004) Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J. Biol. Chem. 279, 2856–2865.PubMedCrossRefGoogle Scholar
  10. 10.
    Liu, M., Zhang, H., Jimenez, X., Ludwig, D., Witte, L., Bohlen, P., and Zhu, Z. (2004) Identification and characterization of a fully human antibody directed against epidermal growth factor receptor. Proc 95th Am. Assoc. Cancer Res. 45, abstract 706.Google Scholar
  11. 11.
    Burtrum, D., Zhu, Z., Lu, D., Anderson, D. M., Prewett, M., Pereira, D. S., Bassi, R., Abdullah, R., Hooper, A. T., Koo, H., Jimenez, X., Johnson, D., Apblett, R., Kussie, P., Bohlen, P., Witte, L., Hicklin, D. J., and Ludwig, D. L. (2003) A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res. 63, 8912–8921.PubMedGoogle Scholar
  12. 12.
    de Haard, H. J., van Neer, N., Reurs, A., Hufton, S. E., Roovers, R. C., Henderikx, P., de Bruïne, A. P., Arends, J. W., and Hoogenboom, H. R. (1999) A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J. Biol. Chem. 274, 18218–18230.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Dan Lu
    • 1
  • Zhenping Zhu
    • 1
  1. 1.ImClone Systems Inc.New YorkUSA

Personalised recommendations